Reduced Relapse risk in patients with AML and NHL after HCMV-replication post haematopoietic stem cell transplantatio
- Conditions
- C92C85Myeloid leukaemiaOther and unspecified types of non-Hodgkin lymphoma
- Registration Number
- DRKS00004300
- Lead Sponsor
- niklinik Essen, Klinik für KMT
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
•Patient's informed consent
•No application of prophylactic ganciclovir or other CMV specific drugs or immunoglobuline preparations in the entire posttransplant course
•regular at least once weekly monitoring of CMV pp65-antigenemia or CMV copy by PCR until day 120 after
Exclusion Criteria
•Relapsed or progressive malignant disease (other than minimal residual disease diagnosed by molecular methods) within 90 days after transplant
•Severe uncontrolled infections
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relapse rate, disease free survival at 24 months post transplant
- Secondary Outcome Measures
Name Time Method overall survival, incidence of GVHD, none-relapse-mortality at 24 months post transplant